MARKET CURRENTS
real-time news and commentary for investors
- Monday, February 13, 7:04 PM More on Charles River Labratories (CRL): Q4 beats both revenue and per share estimates on better than expected product demand and the absence of prior-year write-downs. The company also reafirms FY12 guidance.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
